Daniel I. Goldberg

Cooley advised the underwriters on Seabridge Gold’s $105.2 million follow-on offering. Seabridge Gold is a development-stage company involved in the evaluation, acquisition, exploration and development of gold properties sited in North America. Partner Daniel Goldberg led the Cooley team.

Cooley advised the underwriters in Cerevel Therapeutics’ $253.8 million follow-on offering of 7,250,000 shares of its common stock at a public offering price of $35 per share and the initial purchasers in its $345.0 million Rule 144A convertible notes offering. Cerevel is a clinical-stage biopharmaceutical company pursuing a targeted approach to neuroscience that combines a deep understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system target receptor selective pharmacology to discover and design new therapies. Lawyers Div Gupta, Daniel Goldberg, Eric Blanchard, Mischi a Marca, Jason Savich, Minkyu Park, Amiti Rothstein, Ellie Guadiana, Matt Kong, Eric Delgado and Jordan Verrilli led the Cooley team.

Cooley advised the underwriters in Verona Pharma’s $150 million follow-on offering of 14,260,000 American depositary shares at a public offering price of $10.50 per American depositary share. Verona is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Lawyers Daniel Goldberg, Eric Blanchard, Div Gupta, Charlie Kim, Minkyu Park, Amiti Rothstein and Olivia Creser led the Cooley team.

Cooley advised underwriters on EyePoint Pharmaceuticals’ $115.4 million follow-on offering, with Cowen and Guggenheim Securities acting as joint bookrunning managers. EyePoint Pharmaceuticals is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. Partners Rich Segal and Daniel Goldberg led the Cooley team.

Cooley advised the underwriters on Crinetics Pharmaceuticals’ $125 million follow-on offering of 5,625,563 shares of common stock at a price to the public of $22.22 per share. Crinetics is a clinical-stage pharmaceutical company developing and commercializing novel therapeutics for rare endocrine diseases and endocrine-related tumors. Partners Daniel Goldberg and Kristin VanderPas led the Cooley team.